Trial Profile
Dose-Finding Run-in Phase I Followed by a Phase III, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Crenolanib (Primary) ; Cytarabine; Mitoxantrone
- Indications Acute myeloid leukaemia
- Focus Registrational; Therapeutic Use
- 24 Apr 2020 Status changed from active, no longer recruiting to discontinued.
- 18 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 15 Mar 2017 Status changed from not yet recruiting to recruiting.